Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Cash & Equivalents (2023 - 2025)

Connect Biopharma Holdings' Cash & Equivalents history spans 3 years, with the latest figure at $37.8 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents changed N/A year-over-year to $37.8 million; the TTM value through Sep 2025 reached $37.8 million, changed N/A, while the annual FY2024 figure was $78.2 million, 25.96% down from the prior year.
  • Cash & Equivalents for Q3 2025 was $37.8 million at Connect Biopharma Holdings, down from $40.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $105.7 million in Q4 2023 and bottomed at $37.8 million in Q3 2025.
  • The 3-year median for Cash & Equivalents is $47.7 million (2025), against an average of $62.0 million.
  • The largest YoY upside for Cash & Equivalents was 25.96% in 2024 against a maximum downside of 25.96% in 2024.
  • A 3-year view of Cash & Equivalents shows it stood at $105.7 million in 2023, then dropped by 25.96% to $78.2 million in 2024, then tumbled by 51.62% to $37.8 million in 2025.
  • Per Business Quant, the three most recent readings for CNTB's Cash & Equivalents are $37.8 million (Q3 2025), $40.6 million (Q2 2025), and $47.7 million (Q1 2025).